Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Millie Long(University of North Carolina at Chapel Hill), James Fon(Queen Elizabeth Hospital), Yelina Alvarez(Johnson & Johnson (United States)), Miroslav Fedurco, Monika Augustyn, Curtis A. Baum, R. Draganova, Lingjing Jiang(University of California San Diego), Yoram Bouhnik(Clinique Ambroise Paré), Niazy Abu-farsakh, H. Zhang(Johnson & Johnson (United States)), Domingo Balderramo(Hospital Privado), Lawrence M. Al-Rousan, Jen‐Wei Chou, Silke Jörgens(Johnson & Johnson (United States)), Mary Kavalam(Johnson & Johnson (United States)), Luciana Soledad Brunatto(Western University), Wit Danilkiewicz, Rupa Banerjee, Marjorie Argollo(Universidade Federal de São Paulo), Filip J. Baert, Crispin Corte(Royal Prince Alfred Hospital), Julio De María, Gourdas Choudhuri(Fortis Healthcare), Feng Fan Chiang, Cristina Flores, Chenglong Han(Johnson & Johnson (United States)), Shigang Ding, Ye Chen, Silvio Danese(IRCCS Ospedale San Raffaele), Thomas Baker(Johnson & Johnson (United States)), Jaehee Cheon, Julio Chebli, Hong Chen, Emilio Bermudez Villegas, Changhwan Choi, Martin Bortlik, Jin Ding, Tadakazu Hisamatsu(Kyorin University), Rafal Filip, Ping An, George Duvall, Herlon Escorsi Valerio, Jessica R. Allegretti(Brigham and Women's Hospital), Laurent Peyrin-Biroulet(Inserm), Baisui Feng, David T Rubin(University of Chicago), Matthew Germinaro(Johnson & Johnson (United States)), Federico Argüelles Arias, Antonio Blanco
˜The œLancet. Gastroenterology & hepatology
January 13, 2026
Cited by 6


Related Papers